bioRxivBioengineeringPreprint
Assessing Tumor Microenvironment Characteristics and Stratifying EPR with a Nanobubble Companion Nanoparticle via Contrast-Enhanced Ultrasound Imaging
M. B. Cooley, D. Wegierak, R. Perera, E. C. Abenojar, P. A. Nittayacharn, F. M. Berg, Y. Kim, M. C. Kolios, A. A. Exner
Abstract
The tumor microenvironment is characterized by dysfunctional endothelial cells, resulting in heightened vascular permeability. Many nanoparticle-based drug delivery systems attempt to use this enhanced permeability combined with impaired lymphatic drainage (a concept known as the enhanced permeability and retention effect or EPR effect) as the primary strategy for drug delivery, but this has not proven to be as clinically effective as anticipated. The specific mechanisms behind the inconsistent clinical outcomes of nanotherapeutics have not been clearly articulated, and the field has been hampered by a lack of accessible tools to study EPR-associated phenomena in clinically relevant scenarios. While medical imaging has tremendous potential to contribute to this area, it has not been broadly explored. This work examines, for the first time, the use of multiparametric dynamic contrast-enhanced ultrasound (CEUS) with a novel nanoscale contrast agent to examine tumor microenvironment characteristics noninvasively and in real-time. We demonstrate that CEUS imaging can: (1) evaluate tumor microenvironment features and (2) be used to help predict the distribution of doxorubicin-loaded liposomes in the tumor parenchyma. CEUS using nanobubbles (NBs) was carried out in two tumor types of high (LS174T) and low (U87) vascular permeability, and time-intensity curve (TIC) parameters were evaluated in both models prior to injection of doxorubicin liposomes. Consistently, LS174T tumors showed significantly different TIC parameters, including area under the rising curve (2.7x), time to peak intensity (1.9x) and decorrelation time (DT, 1.9x) compared to U87 tumors. Importantly, the DT parameter successfully predicted tumoral nanoparticle distribution (r = 0.86 {+/-} 0.13). Ultimately, substantial differences in NB-CEUS generated parameters between LS174T and U87 tumors suggest that this method may be useful in determining tumor vascular permeability and could be used as a biomarker for identifying tumor characteristics and predicting sensitivity to nanoparticle-based therapies. These findings could ultimately be applied to predicting treatment efficacy and to evaluating EPR in other diseases with pathologically permeable vasculature.
- assay: imaging
- research focus: cell type annotation
- research focus: spatial domain detection
- research focus: drug response / drug discovery
- approach: microscopy & imaging analysis
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Nanobubbles are Non-Echogenic for Fundamental-Mode Contrast-Enhanced Ultrasound Imaging
J. X. Myers, J. A. Navarro-Becerra, M. A. Borden·bioRxiv·Mar 25, 2022
- Decorrelation Time Mapping as an Analysis Tool for Nanobubble-Based Contrast Enhanced Ultrasound Imaging
D. Wegierak, M. B. Cooley, … A. A. Exner·IEEE Transactions on Medical ImagingPeer-reviewed·Jun 1, 2024
- Exploring the Limits of EPR-driven Tumor Accumulation with Non-opsonizing Nanomaterials
Rinalds Serzants, Baiba Švalbe, … Antons Sizovs·bioRxiv·May 7, 2024
- Preclinical Evaluation of Molecular-Targeted Ultrasound Contrast Agents in a Rabbit Model
Felipe M. Berg, Eric Abenojar, … Agata A. Exner·Bioactive MaterialsPeer-reviewed·Aug 11, 2026
- Intracellular Vesicle Entrapment of Nanobubble Ultrasound Contrast Agents Targeted to PSMA Promotes Prolonged Enhancement and Stability In Vivo and In Vitro
R. Perera, E. Abenojar, … A. Exner·bioRxiv·May 11, 2021
- Efficient ultrasound-mediated drug delivery to orthotopic liver tumors: Direct comparison of doxorubicin-loaded nanobubbles and microbubbles
P. A. Nittayacharn, E. Abenojar, … A. Exner·bioRxiv·Sep 1, 2023